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M. Laird Forrest, PhD; Shuang Cai, PhD; Mark S. Cohen, MD; Yelizaveta Shnayder, MD
Importance: Treatment of locally advanced head and
neck squamous cell carcinoma (HNSCC) uses a multi-
disciplinary approach often limited by the toxicity and
drug resistance of platinum agents.
Objectives: To test whether a nanocarrier-conjugated cis-
platin boosting locoregional drug delivery improves tu-
mor efficacy while decreasing systemic toxicity over sys-
temic cisplatin in a murine model of locally advanced
HNSCC.
Design: A randomized, controlled, in vivo study com-
pared standard cisplatin with nanocarrier (hyaluronan
[HA])–conjugated cisplatin (HA-cisplatin) each at 50%
of the maximum tolerated doses in a murine model of
locally advanced HNSCC (10 mice/arm, each injected with
1  106 MDA-1986 HNSCC cells, with phosphate-
buffered saline and HA-only control arms). Mice were
treated for 3 weeks and observed for 3 additional weeks.
Setting: Academic medical center.
Participants: Forty female Nu/Nu mice. Randomiza-
tion and treatment arms were initiated once tumor vol-
umes reached 30 mm3.
Intervention: Injection with MDA-1986 HNSCC cells
followed by 3 weeks of treatment with cisplatin, HA-
cisplatin, phosphate-buffered saline, or HA only.
Main Outcomes and Measures: Animal weights and
tumor volumes were measured 3 times each week (modi-
fied RECIST [Response Evaluation Criteria in Solid Tu-
mors]). At necropsy, animal kidneys were examined for
nephrotoxic effects and cochleae were examined for oto-
toxic effects.
Results: The mice treated with HA-cisplatin showed su-
perior tumor efficacy (1 with complete clinical response,
3 with partial response, 1 with stable disease, and 5 with
progressive disease) compared with standard cisplatin (no
animals with complete clinical response, 1 with partial re-
sponse, 1 with stable disease, and 8 with progressive dis-
ease), which was statistically significant (P=.003). All con-
trol animals developed progressive disease. Weight loss
and body score were surrogate measures of treatment tox-
icity. The HA-cisplatin group had the least weight loss
(mean [SD], 10.8% [4.7%]) compared with the cisplatin
group (13.6% [5.6%]; P=.25). Body score dropped to 2
or less in all cisplatin-treated mice but not in any HA-
cisplatin–treated mice, which also lacked any histologic
signs of nephrotoxic or ototoxic effects.
Conclusions and Relevance: Nanoconjugated HA-
cisplatin significantly improves tumor efficacy with lower
toxicity compared with standard cisplatin in locally ad-
vanced HNSCC in vivo, justifying additional transla-
tional studies.
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I N THE PAST DECADE, MORE THAN58 000 new cases of head and neckcancers were reported in theUnited States each year. Head andneck cancer is currently the eighth
leading cause of new cancer cases among
men, with more than 40 000 new cases pre-
dicted in the United States for 2012, and it
results in more than 8000 deaths annu-
ally.1,2 Worldwide, more than 500 000 new
cases of head and neck cancers are diag-
nosed each year.3 Overall, head and neck
squamous cell carcinoma (HNSCC) ac-
counts for greater than 90% of head and
neck cancer cases. The median age for di-
agnosis of this disease is in the sixth de-
cade of life, and this cancer type carries a
significant male predominance, with a male
to female incidence ratio of 3:1. Most pa-
tients with HNSCC present with advanced-
stage locoregional disease, for which the
standard of treatment is a multidisci-
plinary approach involving chemoradio-
therapy and surgical resection.4 However,
theoverall5-year survival rate fromHNSCC
remains less than50%despitemultiplecom-
bination therapy regimens during the past
2 decades.5 These combination multidrug-
chemotherapy approaches typically use a
platinum agent, such as cisplatin. The use
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of this cytotoxic drug, while effective against HNSCC, is
limited by its toxicity, specifically nephrotoxicity and oto-
toxicity, as well as by drug resistance in patients with
HNSCC.6,7 Because of the limitations of platinum agents,
novel therapeutic strategies that target head and neck can-
cers more effectively with reduced toxicity profiles are a
priority in current research.
For patients with locally advanced HNSCC, studies
have demonstrated an improved survival rate when ra-
diotherapy is combined with concurrent platinum-
based chemotherapy and surgical resection, increasing
5-year survival rates by up to 6.5%.8,9 Platinum agents,
such as cisplatin, inhibit cancer growth by promoting DNA
binding and cross-linking, thereby triggering apoptosis.
However, this drug also carries systemic toxicities, the
most notable being neurotoxicity, ototoxicity, and neph-
rotoxicity, which are likely related to high peak plasma
concentration levels.10,11 In fact, more than 80% of pa-
tients experience severe toxic effects with current regi-
mens, and more than 75% of patients receiving cisplatin
develop ototoxic effects, which are cumulative and usu-
ally irreversible.12,13
Although platinum agents have a mildly improved sur-
vival benefit in a concurrent setting, the overall survival
and cure rates are still low for HNSCC, and the strong
toxicity profile creates a critical need to improve the safety
and tolerability of this chemotherapy regimen and to en-
hance its efficacy. The use of nanoconjugation with cur-
rent chemotherapeutic agents, such as cisplatin, has been
shown to provide a novel method for drug delivery
through the locoregional lymphatics. This improves drug
delivery and cancer targeting, lowers systemic toxicity,
and still maintains therapeutic systemic levels.14 A pre-
vious study14 demonstrated that hyaluronan (HA), which
has a nanoscopic molecular weight, can be combined with
a chemotherapeutic agent, allowing the drug to be pref-
erentially taken up initially by locoregional tissues and
lymphatic channels without systemic bolus release as a
result of the size and hydrophilicity of the conjugate. This
construct also allows for a sustained-release kinetic pro-
file, permitting improved efficacy at decreased doses.15
In vitro and in vivo models of nanoconjugated HA-
cisplatin have been reported in breast cancer mod-
els.16-18 These studies have shown improved delivery of
the chemotherapeutic agent to the lymphatic system with
a decreased toxicity profile compared with the standard
agent at all doses tested, including lower drug doses.
The most significant, dose-limiting toxicities of cis-
platin therapy are neurotoxicity and nephrotoxicity, both
of which are strongly influenced by peak plasma con-
centration.10 In studies using HA-cisplatin subcutane-
ously for lymphatic drug delivery, the peak plasma con-
centration of platinum from lymphatic HA-cisplatin
nanoparticles was 64% less than that of intravenous cis-
platin and the release was more sustained, consistent with
longer lymphatic retention of the nanocarrier.15 Al-
though HA-cisplatin demonstrated a lower peak plasma
concentration, it maintained an area under the curve simi-
lar to that of platinum in the serum over time, compa-
rable to systemic cisplatin. This equivalent plasma area
under the curve is important for clinical success because
adequate systemic drug levels are required to treat dis-
tant metastases. Nanocarriers can provide a real benefit
by increasing locoregional lymph node basin concentra-
tions compared with standard therapy, since standard sys-
temic therapy achieves poor penetration in the lymph
nodes.19 Thus, lymphatic nanoparticle chemotherapy may
decrease systemic toxicity by eliminating the dangerous
peaks inevitable with intravenous dosing yet provide
equivalent or better distant control by improving the resi-
dence time of anticancer drugs such as cisplatin.
Therefore, we hypothesized that cisplatin, when con-
jugated to nanoscopic HA, will boost drug delivery to the
locoregional tissues and lymphatics, improving tumor ef-
ficacy with decreased systemic toxicity over standard sys-
temic cisplatin in HNSCC. The aim of this study was to
test this hypothesis in a randomized, controlled, trans-
lational study comparing HA-cisplatin with standard cis-
platin for efficacy and toxicity in a murine model of lo-
cally advanced HNSCC with cervical metastases.
METHODS
CELL CULTURE
An aggressive human oral squamous carcinoma cell line, MDA-
1986, was maintained in Dulbecco modified Eagle medium
(Sigma-Aldrich) supplemented with 10% fetal bovine serum,
sodium pyruvate, nonessential amino acids, L-glutamine, a 2-fold
modified Eagle medium–vitamin solution, and a combination
of 1% penicillin and streptomycin sulfate (100 IU/mL and 100
g/mL, respectively; Sigma-Aldrich). Adherent monolayer cul-
tures were maintained in T-75 culture flasks and incubated at
37C with 5% carbon dioxide until they achieved 85% conflu-
ency. The cells were trypsinized using 0.25% trypsin (Sigma
Aldrich) and passaged into T-75 flasks at a density of 1106
cells per 100 L. On experiment days, cells were trypsinized
and counted with a hemocytometer to determine the number
of viable cells.
IN VIVO TUMOR MODEL AND TREATMENT
All animal studies were conducted in accordance with The Uni-
versity of Kansas Institutional Animal Care and Use Commit-
tee guidelines. The MDA-1986 HNSCC cells were prepared in
a 1 PBS solution at a concentration of 1106 cells per 100
L. Cells (100 L) were injected under isoflurane anesthesia
into the retromandibular buccal mucosa of 4- to 6-week-old
female Nu/Nu mice (20-25 g each, Charles River Laborato-
ries) using a 25-gauge needle. Tumor size was measured 3 times
weekly with a digital caliper and confirmed by 2 separate ob-
servers (S.M.C. and N.R.). Tumor volume was calculated using
the following equation:
Tumor Volume=(/6)(Width)2Length,
where volume is measured in cubic millimeters and width and
length are measured in millimeters.
When tumors reached a minimum volume of 30 mm3, mice
were randomized into control arms (PBS or HA only) or one of
2 treatment groups (50% maximum tolerated dose [MTD] cis-
platin or 50% MTD HA-cisplatin). Ten mice were randomized
into each arm for a total of 40 mice. Pharmaceutical-grade cis-
platin was used for the standard treatment groups, as well as to
create thenanocarrier formulationaspreviouslydescribed.17 Treat-
ments in the HA-only control and HA-cisplatin groups were ad-
ministered subcutaneously, 1 to 3 mm from the site of tumor
implantation, and treatments in the PBS control and standard
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systemic cisplatin groups were administered intraperitoneally.
The MTD level reported in mice for cisplatin is approximately
10 mg/kg per weekly intraperitoneal dose.20,21 All treatments were
given once a week for 3 weeks. Mice were then monitored for an
additional 3 weeks on completion of treatment for a total study
period of 6 weeks. Mice were humanely killed before comple-
tion of the experiment if the tumor volume exceeded 1200 mm3
by 6 weeks after inoculation, if weight loss was significant, or if
the body score markedly deteriorated.
HISTOLOGIC STUDIES
On completion of the study, 2 Nu/Nu mice from each treat-
ment arm were examined at necropsy for gross pathologic find-
ings and histologic analysis. The tumor site with surrounding
skin and soft tissues, bilateral kidneys, cochleae, and bilateral
cervical lymph nodes were harvested intact from the mice and
stored in 10% formalin solution for fixation overnight prior to
slide mounting. Mounting with hematoxylin-eosin staining was
conducted by the Department of Pathology at The University
of Kansas Medical Center, Kansas City, and histologic exami-
nation was performed by a blinded board-certified patholo-
gist. Slide images were obtained using digital image-capture soft-
ware (Aperio, version 10.0; Aperio Technologies Inc).
STATISTICAL ANALYSIS
Differences between 2 or more means were compared by un-
paired t test (2 means) and Fisher exact test. Multivariate analy-
sis was performed by 2-way analysis of variance followed by
the Duncan multiple range test (2 means) and Bonferroni post
hoc testing using a statistical analysis software package (SPSS,
version 17.0; SPSS Inc). Significance was defined for P .05.
RESULTS
IN VIVO EFFICACY ANALYSIS
To examine the efficacy of HA-cisplatin in vivo, tumor vol-
umes were monitored in the mice. The control animals
(PBS and HA-only groups) demonstrated a standard ex-
ponential tumor growth curve, with tumor volumes ex-
ceeding 1200 mm3 by 6 weeks after inoculation, leading
to humane killing per the animal care protocol. There was
no difference noted in tumor growth curves between the
PBS and HA-only control animals, confirming that HA by
itself has no direct antitumor activity (Figure 1). Of the
experimental groups, HA-cisplatin was noted to have a bet-
ter overall efficacy, with 4 of the 10 mice (40%) showing
response to treatment, specifically, 1 animal with a com-
plete clinical response and 3 with a partial response, as well
as 1 animal with stable disease. The remaining 5 animals
demonstrated progressive disease (Table). In the stan-
dard cisplatin treatment arm, there were no animals with
a complete clinical response, only 1 animal with a partial
response, 1 with stable disease, and the remaining 8 ani-
mals (80%)withprogressivedisease (Table).Whenweana-
lyzed the results of response among these treatment groups
as a whole, this efficacy was noted to be statistically sig-
nificant (P=.003) (Figure 1). A summary of the clinical
responses to treatment based on modified RECIST (Re-
sponse Evaluation Criteria in Solid Tumors) can be found
in the Table.
IN VIVO TOXICITY ANALYSIS
All mice were monitored for signs of weight loss or de-
terioration in the body conditioning score as a surro-
gate clinical marker of treatment toxicity. Animals in both
treatment groups demonstrated weight loss; however, the
HA-cisplatin–treated mice exhibited the least amount of
weight loss (mean [SD] weight loss, 10.8% [4.7%]) com-
pared with the standard cisplatin-treated mice, which ex-
hibited a mean weight loss of 13.6% (5.6%) (P = .25)
(Figure 2). Body score was examined for all treated ani-
mals and was based on a scale of 1 to 5, where 1 indi-
cates the mouse is emaciated with the entire vertebral col-
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Figure 1. Comparison of head and neck tumor volumes with treatment. The graph shows a composite curve of the tumor volumes for the 10 animals in each
control and treatment group (phosphate buffered saline [PBS], hyaluronan [HA] only, HA-cisplatin, and cisplatin) over time.
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umn distinctly visible; 2, the mouse is underconditioned
with a segment of vertebral column visible; 3, the mouse
is well conditioned; 4, the mouse is overconditioned; and
5, the mouse is obese. In this examination, we noted an
appreciable difference between the 2 chemotherapy
groups. Although all the mice treated with standard cis-
platin sustained a deterioration in body score to a level
of 2 or less throughout the study, requiring that they be
killed prior to study completion, none of the HA-cisplatin–
treated animals exhibited body score deterioration to less
than 2 (P  .01).
PATHOLOGIC ANALYSIS
In the comparison of the 2 treatment arms, a complete
response to treatment was observed in only 1 mouse in
the HA-cisplatin group. This was noted grossly as no evi-
dence of visible or palpable tumor (Figure 3A); con-
versely, visible tumor was observed in all mice in the stan-
dard cisplatin group (Figure 3B). To confirm the
significance of these gross pathologic findings, animal tis-
sues from each treatment group were collected at the time
of necropsy and examined histologically for signs of lo-
cal toxic effects as well as for nephrotoxic and ototoxic
effects. These tissues included the tumor injection sites,
as well as the bilateral cervical lymph nodes, cochleae,
and kidneys. On histologic examination, no animals in
the HA-cisplatin group demonstrated nephrotoxic or oto-
toxic effects. However, the standard cisplatin group dem-
onstrated that half the animals developed nephrotoxic
effects, although no animals in this treatment arm dis-
played any ototoxic effects on examination for cochlear
hair cell damage or on acoustic emission testing.
COMMENT
Locally advanced HNSCC remains a challenge to treat suc-
cessfully. Available chemotherapeutic agents, such as cis-
platin, can be effective but are limited in use because of
their significant local and systemic toxicities as well as drug
resistance. Surgical resection in conjunction with chemo-
radiotherapy, although useful in reducing tumor burden
and extending the time to progression, can be morbid to
the patient, with a spectrum of complications ranging from
minor sequelae, suchas skinandwound infections, tomore
serious complications, such as chyle leaks, carotid rup-
ture, fistulae, and spinal accessory nerve injuries leading
tochronicshoulderdysfunction.22,23 Thesemorbiditieshave
been reported in the literature in as many as 60% of pa-
tients receiving surgical resection.24 Another important
therapeutic challenge involves the poor penetration of cy-
totoxic systemic chemotherapies into the locoregional tu-
mor tissue and lymphatic system. This is due in part to
the unidirectionality of lymphatic flow and the separa-
tion of the lymphatics from the systemic vasculature.19 As
a result, only a small dose of the drug finally reaches the
tumor tissue or the lymph nodes draining the tumor site.
Previous studies have examined the idea of en-
hanced chemotherapeutic agents for the treatment of head
and neck cancer. Some have looked at enhancement of
agents such as cisplatin with molecules such as 2-deoxy-
D-glucose to increase cytotoxicity through metabolic oxi-
dative stress, which showed promising results.25 Others
have begun to examine the role of targeted molecular
agents in the treatment of HNSCC, whether in combi-
nation with agents such as cisplatin or as stand-alone
agents.26 Still other head and neck studies have exam-
ined the use of nanoparticles in the role of tumor sup-
pression in HNSCC models,27 but no studies, to our
knowledge, have looked at the combination of nanopar-
ticles with chemotherapeutic agents in a head and neck
cancer model. Lymphatically delivered chemotherapy is
a novel drug-delivery approach that has been shown to
be effective in other cancer models, such as breast can-
cer, using single agents such as cisplatin in conjugation
with nanoscopic-molecular-weight HA. Previous re-
ports have shown that in vivo usage of this carrier with
cisplatin demonstrated improved locoregional delivery
of the drug to the site of greatest tumor burden in a lo-
cally advanced breast cancer model, with improved ef-
ficacy and decreased toxicity compared with the stan-
dard drug formulations.16-18 Although this mechanism
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Figure 2. Mean (SD) weight change per treatment group of MDA-1986
Nu/Nu mice.
Table. Tumor Response Based on Modified RECIST Criteria
Treatment Group
Animal
1 2 3 4 5 6 7 8 9 10
PBS control PD PD PD PD PD PD PD PD PD PD
HA-only control PD PD PD PD PD PD PD PD PD PD
50% MTD cisplatin PD PD PD PR PD PD PD SD PD PD
50% MTD HA-cisplatin CR PR PD PD PD PR SD PD PR PD
Abbreviations: CR, clinical response; HA, hyaluronan; MTD, maximum tolerated dose; PBS, phosphate-buffered saline; PD, progressive disease; PR, partial
response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
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provides a boost in locoregional delivery, these previ-
ous experiments showed no loss of systemic penetra-
tion with these agents. Once the HA is cleaved from the
drug by hyaluronidase in the lymphatics, the unconju-
gated chemotherapeutic agent is then released into the
system, providing a mechanism for systemic delivery. Pre-
vious studies15,17 of these nanoconjugated agents in com-
parison with standard agents have been performed to mea-
sure systemic absorption. Those studies demonstrated
comparable levels of systemic penetration between the
nanoconjugates and standard therapy. Also, intratu-
moral and lymphatic levels of HA-cisplatin compared with
systemic cisplatin demonstrated significantly increased
levels of cisplatin at these sites in the HA-cisplatin group.13
The results of the present study demonstrate that HA-
cisplatin treatment significantly improves efficacy (as dem-
onstrated by better RECIST tumor response) over stan-
dard treatment when delivered at 50% MTDs in a murine
model of locally advanced HNSCC. The nanoconjugate
group had a 40% response rate (4 animals), with a 10%
complete clinical response rate (1 animal) compared with
an overall 10% partial response rate (1 animal) in the stan-
dard current cisplatin therapy at 50% MTD. Therefore,
even at 50% of standard treatment doses, the nanocon-
jugate demonstrated superior efficacy.
The standard treatment of 50% MTD cisplatin re-
sulted in significant morbidity and mortality, with all mice
requiring humane killing before study completion be-
cause of significant clinical toxic effects as evidenced by
decreased body scores and long-term weight loss. In con-
trast, this was not seen in the 50% MTD HA-cisplatin
group, although a roughly 10% weight loss was noted in
this group during treatment. In similar studies with HA-
cisplatin in a locally advanced breast cancer model, this
10% weight loss was noted to be transient when the mice
were observed for a longer period, and it was no longer
present beyond 3 weeks after the completion of treat-
ment. Because the present study followed up the mice
for a total of 3 weeks after the completion of treatment,
it is unclear whether the weight loss noted in the HA-
cisplatin group is also transient or is a permanent effect.
Although nephrotoxic effects were demonstrated in the
standard treatment group and not in the nanoconjugate
group, ototoxic effects were not demonstrated in either
group. Ototoxicity is a prevalent complication in hu-
man dosing of cisplatin, but it is believed to result from
a cumulative dose effect. Therefore, it is likely that this
sequela was not seen in the standard group because the
short treatment course of 3 weeks and the reduced 50%
MTD dose were not enough to create the cumulative dose
effect that would result in ototoxic effects. Further trans-
lational investigation with longer follow-up and treat-
ment regimens will provide an improved understanding
of the chronic toxicity of the HA-cisplatin treatment.
In conclusion, this study demonstrates that nanocon-
jugated therapy with HA-cisplatin exhibits improved an-
ticancer efficacy against a murine model of locally ad-
vanced HNSCC compared with standard cisplatin therapy
at the same dose with a reduced toxicity profile. This ef-
fect was evident even with a reduced (50% MTD) dose of
cisplatin. The limitations of this study include a small
sample size for each group, a short (3-week) duration of
therapy, and a short follow-up. Also, the nature of this short
study does not address the efficacy of this treatment against
distant metastases. Despite these limitations, statistical sig-
nificance was observed when we compared antitumor ef-
ficacy and body scores between the HA-cisplatin–treated
mice and the standard cisplatin–treated group.
Because this system uniquely targets the lymphatics and
provides a locoregional boost without the loss of systemic
penetration, it has potential to be translated clinically in
patients who have locally advanced HNSCC, with a goal
of reducing tumor burden and lymphatic disease before
surgical resection to improve recurrence rates and possi-
bly even survival. Other prospective applications include
using it as a potential treatment for patients with locore-
gional recurrence inwhomtraditional systemicagentshave
failed due to toxic effects or drug resistance, in which a
locoregional boost could limit the drug’s systemic toxic-
ity and improve locoregional tumor penetration to poten-
tially overcome resistance. Finally, given its ability to im-
prove antitumor efficacy with a reduced dose, this
nanoconjugatedagentcouldbeextremelyusefulwhencom-
bined with concurrent radiotherapy in the adjuvant treat-
BA
Figure 3. Photographs of tumor response in Nu/Nu mice after treatment. A, A mouse treated with nanocarrier (hyaluronan [HA])–conjugated cisplatin
(HA-cisplatin). B, A mouse treated with standard cisplatin.
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ment of HNSCC. Data from this study, however, provide
a solid foundation for additional translational proof-of-
concept studies to advance this delivery system toward po-
tential clinical applications in which novel treatment strat-
egies that carry less toxicity and improved efficacy are
needed for patients with advanced HNSCC.
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